[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498191":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":34,"responsibleParty":101,"collaborators":32,"id":103,"slug":32,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":32,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":32,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Amgen","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Apremilast","EXPERIMENTAL","Participants with a weight between ≥ 12 kg to \\\u003C 20 kg will receive apremilast 10 mg BID (twice a day), participants with a weight between ≥ 20 kg to \\\u003C 50 kg will receive 20 mg BID, and participants with a weight ≥ 50 kg will receive apremilast 30 mg BID.",[13],"Drug: Apremilast",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Oral tablets or liquid suspension",[9],[20,21,22],"AMG 407","Otezla","CC-10004",[24],{"name":25,"affiliation":5,"role":26},"MD","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Amgen Call Center","CONTACT","866-572-6436",null,"medinfo@amgen.com",[35,47,57,67,76,86,95],{"facility":36,"status":37,"city":38,"state":32,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":32},"General Hospital of Thessaloniki Ippokrateio","RECRUITING","Thessaloniki","54642","Greece",{"type":42,"coordinates":43},"Point",[44,45],22.93493,40.64072,{"lat":45,"lon":44},{"facility":48,"status":37,"city":49,"state":32,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":56,"contacts":32},"Meir Medical Center","Kfar Saba","4428164","Israel",{"type":42,"coordinates":53},[54,55],34.90694,32.175,{"lat":55,"lon":54},{"facility":58,"status":37,"city":59,"state":59,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":66,"contacts":32},"Hospital Universitari i Politecnic La Fe","Valencia","46026","Spain",{"type":42,"coordinates":63},[64,65],-0.37966,39.47391,{"lat":65,"lon":64},{"facility":68,"status":37,"city":69,"state":32,"zip":70,"country":61,"cosmosGeoPoint":71,"geoPoint":75,"contacts":32},"Hospital Universitario Ramon y Cajal","Madrid","28034",{"type":42,"coordinates":72},[73,74],-3.70256,40.4165,{"lat":74,"lon":73},{"facility":77,"status":37,"city":78,"state":32,"zip":79,"country":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":32},"Hacettepe Universitesi Tip Fakultesi Hastanesi","Ankara","06100","Turkey (Türkiye)",{"type":42,"coordinates":82},[83,84],32.85427,39.91987,{"lat":84,"lon":83},{"facility":87,"status":37,"city":88,"state":32,"zip":89,"country":80,"cosmosGeoPoint":90,"geoPoint":94,"contacts":32},"Istanbul Universitesi Cerrahpasa Tip Fakultesi","Istanbul","34098",{"type":42,"coordinates":91},[92,93],28.94966,41.01384,{"lat":93,"lon":92},{"facility":96,"status":37,"city":88,"state":32,"zip":97,"country":80,"cosmosGeoPoint":98,"geoPoint":100,"contacts":32},"Umraniye Egitim ve Arastirma Hastanesi","34764",{"type":42,"coordinates":99},[92,93],{"lat":93,"lon":92},{"type":102,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100498191",false,"NCT05767047","A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis","A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis","Inclusion Criteria:\n\n* Informed consent \u002F assent obtained\n* Must have completed Week 52 on treatment on core study and must be \\\u003C 18 years of age at the time the informed consent document is signed\n* Age and sex specific body mass index (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) at enrollment\n* Willing to adhere to study visit schedule and protocol requirements\n* Must have acceptable benefit\u002Frisk for continued treatment with apremilast\n\nExclusion Criteria:\n\n* Answer \"yes\" to any question on C-SSRS at Week 52 visit of core study\n* Scheduled surgery or other interventions that would interrupt study participation\n* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose\n* Female participants planning to become pregnant while on study through 30 days after last dose\n* Female participants of childbearing potential with positive pregnancy test at Week 0\n* Known sensitivity to any products to be administered during dosing","ALL","5 Years","18 Years",{"count":113,"type":114},48,"ESTIMATED","INTERVENTIONAL",[117],"PHASE3","The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.",[120,121],"Behçet's Disease","Juvenile Psoriatic Arthritis",[123,120,121,9,20,21],"Oral Ulcers","2025-11-26",{"date":126,"type":127},"2025-12-01","ACTUAL",{"date":129,"type":127},"2023-03-23",{"date":131,"type":114},"2036-03-17",{"name":5,"class":6},7]